AllianceBernstein
BHVN

AllianceBernstein’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

AllianceBernstein’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-25,000
Closed -$1.36M – 3227
2019
Q4 		$1.36M Buy
+25,000
New +$1.24M ﹤0.01% 2144
2019
Q3 		– Sell
-50,000
Closed -$2.19M – 3238
2019
Q2 		$2.19M Buy
+50,000
New +$2.82M ﹤0.01% 1921

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

AllianceBernstein's BHVN Position: Q4 2022 in Review

AllianceBernstein sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 314,412 shares — an estimated $47.5M sold.

AllianceBernstein first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $159M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • AllianceBernstein reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • AllianceBernstein sold 314,412 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $47.5M.
  • AllianceBernstein first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • AllianceBernstein's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $159M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on AllianceBernstein's 13F filing for Q4 2022, filed 15 Feb 2023.